In this report, we have presented evidence that colon cancer cells with mutations in BRAF are also resistant to HSP90 inhibitors, including AUY922 that is currently in clinical trials for the treatment of wild-type KRAS colon cancers [14]. Here, BRAF is linked to malignant colon neoplasm.